What did ArborGen Holdings Limited announce?

ArborGen Holdings Limited (NZX: ARB) filed “ArborGen Holdings Annual Shareholder Meeting” with NZX on 14 September 2026, as an agm announcement.

From the announcement:“CHAIR’S ADDRESS – DAVE KNOTT I want to use my address to talk directly about where ArborGen stands today, the progress we have made, what comes next and other matters that we know are important to shareholders.”
When was it filed?
14 September 2026
Where is the original?
NZX announcement
ArborGen Holdings Limited logo

ArborGen Holdings Annual Shareholder Meeting

AGM14 September 2026ARBIndustrials

1


2026 ANNUAL SHAREHOLDERS’ MEETING SPEECHES


1. WELCOME

Good morning and welcome to ArborGen’s annual shareholders meeting. I am Dave

Knott, Chairman of the Board.

It’s great to be back in New Zealand to meet shareholders and talk about ArborGen’s

performance. Thank you for joining us today.

2. CHAIR’S ADDRESS – DAVE KNOTT

I want to use my address to talk directly about where ArborGen stands today, the

progress we have made, what comes next and other matters that we know are

important to shareholders.

There is much about ArborGen that gives us confidence. We have strong market

positions, valuable intellectual property and genetics, long-standing customer

relationships, and a growing business in Brazil with significant long-term potential.

However, our overall performance is not yet where we hoped it would be and we

recognise that the shareholder experience has been disappointing.

In particular, our share price remains at a level that none of us are satisfied with, and

low liquidity in ArborGen shares is a genuine concern for some shareholders.

As a Board, we are very conscious that ultimately we need to demonstrate the value

within ArborGen through stronger performance and better returns.


3. REGIONAL MARKET LOOKBACK

It’s worth looking back at our market development since the sale of our Australia and

New Zealand business in FY22, following which we focused our resources on our two

core markets, the US South and Brazil. Since then, those markets have followed quite

different paths.

Brazil

In Brazil, we moved quickly to build scale in a large and growing forestry market.

Revenue increased from around $8 million in FY22 to approximately $30 million by

FY26, growing from 16% to more than 40% of our Group revenue. Over that period, we

acquired and leased additional nurseries, expanded production and increased total

capacity to more than 135 million seedlings annually, including contract growers.

2

That rapid expansion also created challenges. Systems, processes and financial

disciplines did not always develop at the same pace as the business, while drought-

related production constraints in recent years affected yields and increased costs.

Our focus has therefore shifted from building scale to consolidating what we have built.

We have strengthened the team, financial processes and production planning; are

shifting sales to higher-value protected clones, and are focused on improving yields and

productivity. This is an ongoing process with improvement initiatives still underway.

US South

The US has followed a different path.

In FY22, the business was performing strongly, with record advanced genetics sales. We

continued to invest in higher-value MCP genetics, container capacity and our nursery

network.

However, weaker housing construction, reduced timber harvesting and the structural

decline in pulp demand progressively reduced seedling demand. What initially appeared

cyclical has developed into a more fundamental change in the market.

We have responded by reducing costs and right-sizing the footprint, including nursery

rationalisation and the sale of non-core operations – a process that is ongoing this year.

At the same time, we continue to invest behind our key competitive advantage:

advanced genetics. In a market increasingly focused on higher-value sawtimber, we

believe the ability to grow better-performing trees remains highly relevant.

4. FY26 PERFORMANCE SNAPSHOT

In FY26, we delivered a result ahead of revised guidance and within the range originally

set.


Revenue was a record result, despite the weak US market. Earnings and margin also

recovered year on year.


This was supported by increasing average sales prices as our strategy to move

customers to higher value products bears fruit. This remains one of our strategic

priorities.


5. MARGIN STORY

Margins have moved around as the business has grown and market conditions have

changed.

In Brazil, rapid expansion has brought significant revenue growth, but also the costs of

building capacity, integrating new operations and addressing production and process

challenges.

In the US, lower volumes have reduced utilisation of our nursery network and increased

the impact of fixed costs.

3

At the same time, we have continued to invest in higher-value products - advanced

genetics and containerised seedlings – and this remains an important driver of margin

over the longer term.

Our focus now is on building revenue, reducing costs and converting the scale and

capability we have built into stronger returns.

6. CASH GENERATION AND DEBT REDUCTION

That focus on stronger returns also needs to translate into improved cash generation.

Over recent years, we have invested significantly in building ArborGen’s growth

platform, particularly in Brazil, while challenging conditions in the US have constrained

earnings and cash flow. As a result, debt is higher than we would like.

Our priorities are now changing. With much of the investment required to establish the

Brazil platform behind us, we are increasingly focused on generating more cash from

the assets and capacity already in place.

That means disciplined capital expenditure, tighter working capital management,

improved margins and productivity, and continuing to review our asset base for

opportunities to release capital.

Reducing debt is a clear priority for the Board. Stronger operating cash flow, together

with proceeds from the divestment of surplus or non-core assets where appropriate,

will be directed towards deleveraging. The sale of the Ridgeville building has reduced

debt by US$8.6m, with a flow-on benefit from lower interest costs this year.

This is an important part of the next phase for ArborGen: translating earnings growth

into cash, strengthening the balance sheet and creating greater flexibility for the future.

7. SHAREHOLDER VALUE

We recognise that shareholders have heard us talk about ArborGen’s potential for some

time. Our priority now is to convert that potential into stronger earnings, cash flow and

returns.

There is no single initiative that will achieve this. It requires continued profitable growth

in Brazil, improving the performance and cost structure of the US business, and

disciplined capital allocation. Importantly, growth needs to create value, not simply add

scale.

Some shareholders have asked whether ArborGen should undertake another strategic

review, particularly given the performance of our share price.

Our last review in 2021 followed an unsolicited approach to acquire the company.

Rather than simply reject an offer we believed materially undervalued ArborGen, we

appointed PwC to test a broad range of alternatives, including asset and company sales

and a potential US listing.

That process resulted in the sale of our Australian and New Zealand operations for

NZ$22.25 million. However, the proposals received for the wider business did not

represent better value than retaining and investing in the US and Brazil.

4

Much has changed since then. The US market has undergone a significant structural

reset, while Brazil has developed into an important growth business.

We do not believe another formal review simply for the sake of undertaking a process is

necessarily the answer. But we are not closed to alternatives.

The Board continues to assess our portfolio, capital allocation and opportunities to

realise greater value.

Our objective is not to preserve ArborGen in its current form. It is to maximise value for

all shareholders.

Share price and liquidity

I also want to address our share price and liquidity.

ArborGen has a relatively limited free float – around 50% of issued capital - and low

trading volumes.

The Board has acted where appropriate and our 2024 share buyback resulted in

approximately 5.9 million shares being acquired and cancelled.

We cannot determine the price at which our shares trade, but we can improve the

performance of the business and allocate capital carefully.

Ultimately we believe that stronger financial performance is the most sustainable way

to create shareholder value.

Leadership transition

As shareholders may know, Justin Birch recently resigned as Chief Executive after three

years with ArborGen.

On behalf of the Board, I acknowledge Justin’s contribution. His departure also provides

an opportunity to consider the leadership ArborGen needs for its next phase.

We are also aware of shareholder interest in the equity arrangements put in place when

Justin was appointed. Tenure-based restricted shares – a common remuneration

practice in the US -vested in accordance with the terms approved at the time.

Performance-based shares under the long-term incentive plan were not awarded as the

targets were not met.

The Board recognises that executive remuneration is judged alongside company

performance and shareholder returns.

For future leadership, we will ensure executive reward is clearly aligned with sustained

performance, delivery against our strategic priorities and long-term shareholder value.

8. STRATEGIC PROGRESS AND NEXT STEPS

The next phase for ArborGen is about execution. I have talked about our three priorities

for this year.

We have a strong position in the US South, notwithstanding the structural challenges

facing that market, and an increasingly valuable growth platform in Brazil.

5

Our task is to make more of those positions.

In Brazil, that means consolidating and integrating our operations following a period of

rapid expansion, capturing the growth available to us and continuing to increase the

contribution from higher-value protected clones.

In the US, it means ensuring the business is configured appropriately for a structurally

smaller market, while continuing to upsell our customers to the higher quality advanced

genetics that differentiate ArborGen.

We need to expand our margins – firstly by growing sales of higher value products, but

also by improving our focus on commercial and operational excellence and optimising

our existing assets.

Across the Group, we need to generate stronger cash flow, drive profit and be

disciplined about where we invest.

We will also continue to challenge our assumptions about the business and remain

open to opportunities that could deliver greater value.

9.

FY27 OUTLOOK

For FY27, we are targeting a continued improvement in revenue, cash generation and

debt reduction. This will be driven by continued volume growth in Brazil, some revenue

growth in the US, further improvements in operating leverage, and continued

investment in advanced products.

We are not providing guidance at this time, but will look to do so with the half year

results in November.

10. LOOKING AHEAD

I recognise that shareholders, particularly those who have been with ArborGen for

many years, want to see tangible evidence of progress.

That is a reasonable expectation and one which the Board shares. We are shareholders

too, and our interests are aligned in wanting ArborGen's underlying value to be

reflected in the returns delivered to all shareholders.

We believe ArborGen has valuable assets, strong market positions and a genuine

growth opportunity in Brazil. Our priority is to convert those strengths into improved

earnings, cash generation and, ultimately, better returns for shareholders.

It’s important to remember the timelines that we are working with. Our customers are

planting for forests they won’t harvest for 25 years or more.

In today’s market, where volumes are constrained, the path to earnings resilience is

through quality. While they may be planting less, our customers are increasingly

planting higher quality seedlings – an area in which we excel.

As VP of Product Development, interim Chief Executive Patrick Cumbie has played an

essential role in building ArborGen’s leadership position in advanced genetics. I’ll now

hand over to him to talk to you about our product portfolio and the position of strength

it gives us in the market.

6


11. INTERIM CEO’S INTRODUCTION


Good morning. It’s good to be here with you today as we talk about ArborGen, both the

past year and looking forward.


As you are all aware this is a season of leadership transition for the company. I am

grateful for the opportunity to serve the ArborGen team in this interim role.


I have been in the industry for 24 years and with ArborGen for over 16, starting as a

project scientist focused on biotechnology projects and then shifting over the years to

manage and lead all of the pine development efforts before moving to senior

management.


Forest genetics is a passion and I’m excited to help lead the company through this

time so we can continue to provide superior genetics to the market, educate the

market on the value proposition, and provide excellent quality and service to our

customers and partners.


Working on Product Development has given me a unique opportunity to be connected

both to our sales team to support partners and customers, but also very much

integrated into our operations team through orchard strategy, genetic deployment,

and quality assurance.


We are poised to move forward to successfully execute our strategy of higher adoption

of MCP in the US, and in Brazil both advanced families of pine and protected clones of

eucalyptus.


12. LEADERSHIP FOCUS 2026


As Dave has said, we have three strategic priorities this year – to build sales of high

value products, expand our margins, and generate cash to support profit and debt

reduction.


The management team have identified four critical areas to help us be

successful. These are not a departure from our previous focus, but represent

a streamlining of what is essential, providing a clear focus for our team.


Firstly, people and culture ... we have no hope of achieving operational or financial

success without a committed group. As mentioned in years past, we have been working

to put the right people into leadership as well as technical and operational roles.


The long-term nature of our industry and our business also means we need a team who

is committed to the mission of the company. Especially in a time of transition, we are

focusing on strengthening our culture to make sure we put our best foot forward in

achieving sales, production, and quality goals. The combined experience, talent and

institutional knowledge across our two regions is something our competitors can’t

replicate overnight.


7

Next is genetics leadership: Our genetic resources in the US are a tremendous asset.

We will continue to produce the best loblolly pine seedlings available in the market,

invest in product development efforts to prepare the next generation of trees, orchards,

seeds, and products going out to customers. This past year we refreshed our pine

products which I’ll talk about today.


In Brazil the supply of US pine genetics continues to be in demand, and the protected

clones of eucalyptus will be the focus as we work to also develop our own proprietary

clones for the market.


Third is Operational Excellence: As the market headwinds continue to be a challenge in

the US, it is imperative to make necessary adjustments to reduce costs and we’re

looking closely at how, where and what we grow.


In Brazil, we significantly expanded our production capacity over the last two years with

the nursery acquisitions and new partnerships. Now it is time to make them “one

company” as we work to align operating efficiency and management of different

facilities.


Finally, financial stability: We have invested heavily in expanding our US container

product and nursery capacity in Brazil. Our focus now is on maximising the value of

those investments to generate cash, reduce net debt, and increase our ability to make

measured investments for growth in both geographies.



13. THE ‘GENETICS DIVIDEND’

Having worked in Product Development for over 16 years, I wanted to share my

thoughts on ArborGen’s products and offer and what gives us such a strong position in

the market.


Growers are making decisions today that won’t deliver payback for another 25 years.

The seedlings they put in the ground shape growth, form, wood properties, health and

survival - then compound across time, hectares and harvest decisions, influencing

everything from thinning options to log mix at final harvest.


That’s the genetics dividend: an important upfront choice that can deliver outsized,

long-term returns.


Genetics has been recognised in the US for loblolly pine for decades, but

understanding and confirming the value creation with mature stands has been lacking.


We are now getting very positive feedback from customers who invested in MCP® 10 to

15 years ago and are thinning the plantations. One customer has invested significantly

to assess the difference between OP and MCP genetics in operational plantations, and

we are excited to see that operational data confirms and reinforces the value

proposition in MCP.


Traditionally, growers have had access to pulp markets which provided a mid-rotation

cash flow from thinnings. This often drove the decision on how many trees

per hectare to plant. With the loss of these markets in some areas, growers

are considering planting fewer trees.

8


For many, it’s not a dramatic reduction although some growers are looking to

make larger decreases. This could impact the overall market size, but will also

drive growers towards better, more advanced genetics. In essence, with fewer trees per

hectare planted, the success of each tree planted becomes more important.


Growers need every tree to have a high probability of producing sawtimber. Where

traditional Open-pollinated families might produce stems with 40-60% quality stems,

MCP offers 75-85% quality stems, a much better option when you reduce your planting

densities by 15-25%.


14. SMARTER SEEDLINGS. CLEARER CHOICES


This past year in the US, we refreshed our pine product categories with clear brand tiers

for our MCP pine seedlings. Building on a decade of testing across the Southeast and

deeper integration of proprietary and cooperative data, the team developed the AG

Score, a single index that evaluates families in each region based on the traits that

most impact plantation success. Each tier is designed to make seedling selection easier

and highlight tangible performance benefits.


We’ve had positive feedback from customers on the rebranding and the data driven

approach. Value creation is about growing more tons of wood that will qualify as

sawtimber rather than pulpwood. The AG score index and refreshed product categories

help customers understand the opportunity that comes with selecting higher

performing genetic products.


15. CUSTOMERS REALISING SIGNIFICANT GAINS

We are seeing real-world forest plantations planted with MCP Pro+ seedlings showing

significant growth improvements over OP seedlings, and the sawtimber at harvest is

projected to be more than double that of OP due to improvements in yield and quality.


16. EUCALYPTUS

In Brazil, we continue to focus on producing protected clones that are licensed from

other companies.


However, our product development team is working to bring ArborGen clones to the

market, including testing the clones across multiple regions to identify which perform

the best in a specific geography.


17. MARKET OPPORTUNITY


Our advantage is the combination of a sustained decades-long research and

development programme, rigorous field testing and data capture, and the operational

ability to commercialise winning genetics at scale.


Our strategy is designed to grow the adoption of advanced genetics while strengthening

the operating foundation that allows us to deliver performance, consistency and service

at scale.

9

We are intentionally focused on markets where the combination of scale, long-term

planting demand and customer sophistication makes advanced genetics most valuable.


The market opportunities in Brazil remain compelling and we are well positioned to

convert those into sustained earnings growth. While the US South is more challenging,

we remain one of the leading suppliers of advanced genetics seedlings in the market.


The emerging carbon forestry market also presents a meaningful long term opportunity,

and we are already partnering with carbon developers and co-hosting industry events

that position ArborGen at the centre of this conversation.


Thank you.

---

1
ANNUAL

SHAREHOLDERS’ MEETING

15 September 2026

ArborGen 2026 ASM

INTRODUCING
THE BOARD

2

David Knott – Chairman

Appointed 19 August 2021

George Adams – Independent Director

Appointed 12 August 2019

Standing for re-election

Paul Smart – Independent Director

Appointed 21 August 2018

Standing for re-election

Unanimously supported by the Board

Thomas Avery – Independent Director

Appointed 18 July 2018

Standing for re-election

Unanimously supported by the Board

Ozey Horton – Independent Director

Appointed 11 July 2018

ArborGen 2026 ASM

David Knott
CHAIR OF THE BOARD

ArborGen 2026 ASM

LOOKBACK REGIONAL MARKETS
0

10

20

30

40

50

60

70

80

FY22FY23FY24FY25FY26

Sales Revenue

US $m

BrazilUS South

Sale of ANZ business in FY22 → focus on US South and

Brazil

Brazil

•Rapid expansion, growing pains now being addressed

•Opportunity: Large and growing market with

increasing demand for higher quality seedlings

US South

•Market steadily weakened → structural downturn

•Opportunity: Focus on higher value vs volume

ArborGen 2026 ASM

4

FY26 PERFORMANCE SNAPSHOT
10.1

9.2

12.8

8.8

11.5

FY22FY23FY24FY25FY26

Adjusted US GAAP EBITDA

US $m

47.5

56.1

67.7

63.2

68.2

360m

375m

369m

328m

324m

FY22FY23FY24FY25FY26

Sales Volume and Revenue

US $m

Sales RevenueSales Volumes

•Record revenue result – supported by higher

average selling prices

•Adjusted US GAAP EBITDA up 31% YOY, despite

weakness in US market

•Earnings increased ahead of revenue – driven

by revenue growth, pricing, mix and cost

efficiencies translating into higher operating

earnings

Strategic priority: High-value sales mix

ArborGen 2026 ASM

5

MARGINS REFLECT GROWTH AND MARKET CYCLE
Growth investments made → platform for significant operating leverage

34

35

38

33

33

FY22FY23FY24FY25FY26

Gross Margin % (US GAAP)

FY22 – FY26: Investment into growth opportunity in Brazil

FY26 margins reflect:

•Lower US volumes + under-utilised capacity

•Brazil scaling costs + labour/input inflation

•Some pricing pressure on market-clones in Brazil

Next step to convert recent investment into stronger

margins through increasing sales and lower costs

Strategic priority: Margin expansion

Investment in growth initiatives

ArborGen 2026 ASM

6

CAPITAL MANAGEMENT
Increase in borrowings reflects investment in growth

FY22 – 26: Invested substantially to grow the business

– expansion of production capacity in Brazil, higher

value genetics, container seedlings

Actions taken to improve cash flow and reduce debt:

•Capex reduced to $4.1m in FY26 (FY25: $7.7m)

•Right sizing US business – people, footprint

•Sale of non-core assets and property to release

capital: Ridgeville HQ in July 2026 - net proceeds of

$8.8m used to pay down debt

Strategic priority: Cash generation and debt

reduction

-1.5

-1.4

-6.5

-4.3

11.5

13.0

14.4

20.9

25.2

FY22FY23FY24FY25FY26

Net Debt and Cash Generation

Investment in growth

Net debt

post-HQ sale

ArborGen 2026 ASM

7

SHAREHOLDER VALUE
8

Maximise value for all shareholders

•Focus on converting potential into stronger earnings, cash flow and returns

•Continue to assess portfolio, capital allocation and opportunities to realise greater value

•Remain open to strategic proposals

Share price and liquidity

•Challenge: Limited free float → small trades have disproportionate impact on share price

•Lack of visibility and institutional support for micro-cap stocks

•Stronger financial performance is the most sustainable way to create shareholder value

8

ArborGen 2026 ASM

STRATEGIC PROGRESS AND NEXT STEPS
9

FY22 – FY25

Reshape and Invest for Growth

FY26 – FY27

Strengthen

FY28 onwards

Extract Value

✓Sale of ANZ

✓Exit out of pandemic

disruption

✓Rapidly scaled Brazil

✓Increasing shift towards

higher-value genetics

✓Navigated prolonged

cyclical downturn in US

✓Improvements to the

operating platform

✓Building supply resilience

•High value sales mix: accelerate

sales, adoption and development of

advanced products

•Margin expansion: continuously

improve operational performance;

optimise productivity and utilisation

of existing assets

•Cash generation and debt

reduction: consolidate Brazil after

rapid growth; right-size US for

structural downturn; rationalise non-

core activities and property

•Profitable growth in Brazil

•Optimise US returns

•Higher-value product mix

•Operating leverage

•Margin expansion

•Cash generation

•Debt reduction

•Unlock Group synergies

ArborGen 2026 ASM

FY27 OUTLOOK
For FY27, ArborGen is targeting continued improvement

in revenue, cash generation and debt reduction

•Continued volume growth in Brazil, supported by

increased capacity and ongoing customer transition to

protected clones

•Some revenue and volume growth in the US South,

driven by higher-value products and market share gains

•Further improvements in operational efficiency, cost

management and increasing integration and

collaboration between the US and Brazil

•Continued investment in higher-value and added value

products

ArborGen is entering

FY27 with a stronger

operational platform, a

more resilient business

and clear opportunities

for growth.

The deliberate and

disciplined choices

being made today will

enable the business to

perform well in a more

subdued US market,

while continuing to

grow in Brazil.

ArborGen 2026 ASM

10

POSITIONED TO PERFORM
•Clear strategy

•Market leadership position in target markets - US South and Brazil

•Unparalleled product portfolios in each of our core markets

•Focused on value growth

•Multi-decade investment in research and intellectual property

•Service more than 2,000 customers each year

•Production capacity of ~500 million+ seedlings per annum

ArborGen 2026 ASM

11

Patrick Cumbie
INTERIM CEO

ArborGen 2026 ASM

LEADERSHIP FOCUS 2026
13

Strategic

Priorities

Build sales of high value

products

Expand

margins

Cash generation and

debt reduction

LEADERSHP PRIORITIES

People and CultureStrong management. Committed and passionate team.

Experts in our field. Customer focused.

Genetics LeadershipLeverage our strengths. Invest in product development.

Build market share and leadership.

Operational Excellence Right-size the US. Consolidate Brazil. Improve efficiency and

productivity.

Financial Stability Build a leaner operation that can scale as demand grows.

Maximise the value of investments.

ArborGen 2026 ASM

THE GENETICS DIVIDEND
14

ArborGen 2026 ASM

Superior Trees

Straighter, higher value,

more disease resistance,

increased harvest

Genetically

Improved Seedlings

Offspring with enhanced

traits from seed

orchards

Seed Orchards

Controlled environments

where selected parent

trees produce improved

seeds

Selected Parent

Trees

Superior trees based on

desirable traits

Open Pollinated

Trees

Naturally pollinated with

genetic variability

Genetically

Superior Trees

SMARTER SEEDLINGS. CLEARER CHOICES.
15

ARBORGEN SCORE

OPReliable performance and

balanced return

OP ProImproving productivity

without added cost

MCPBoosting sawtimber potential

and overall value

MCP-

PRO

Maximising growth, quality

and harvest returns

MCP-

PRO +

For top-tier investors seeking

the highest ROI

PRODUCT CATEGORIES

ArborGen 2026 ASM

Volume

Gain

Sawtimber

Potential

Total

Tons/Acre

ArborGen

Score

$/Acre at

Clearcut

50%15%19060

20%

25%

30%

35%

60%

75%

75%

75%

208

216

229

238

$2,348

$2,851

$3,454

$3,808

$4,068

+$500/acre

+$1,100/acre

+$1,500/acre

+$1,700/acre

71

82

96

104

CUSTOMERS ARE REALISING SIGNIFICANT GAINS
•Significant hectares of commercial

MCP plantations are now reaching

mid-rotation ages

•Real-world data is being captured

and customers are seeing solid gains

from MCP

•In some cases we are seeing

plantations on track to produce

100% more sawtimber over OP

genetics

Overall, MCP plantations have larger

volume and better quality than OP

plantations

16

ArborGen 2026 ASM

15202530

50

100

150

200

Age (years)

Total Volume (tons/acre)

Total Volume by Age with Genetic Trends

Genetics

MCP-Pro+

OP

Mean Marginal Product Volume Gains at Age 25 vs OP

50

100

Marginal % Gain

0

Genetics

Product Type

Chip-n-Saw

Pulpwood

Sawtimber

PROTECTED EUCALYPTUS CLONES OFFER EXCEPTIONAL YIELD GAINS
Protected eucalyptus clones offer exceptional yield gains over market clones in Brazil

•We test and evaluate licensed and proprietary genetics for the market across Brazil

•Screened for propagation, growth, wood properties, diseases

•Data and results guide our selection of materials in the market

17

0

10

20

30

40

50

60

70

80

90

Campo

Novo

Parecis -

MT

Ribas do

Rio Pardo

- MS

Nova

Mutum -

MT

Selvíria -

MS

Ribas do

Rio Pardo

- MS

Igreja

Nova - AL

Nova

Mutum -

MT

Ribas do

Rio Pardo

- MS

Bauru -

SP

Bauru -

SP

Borebi -

SP

Nova

Mutum -

MT

Bocaiúva

- MG

Francisco

Dumont -

MG

4,14,44,64,74,85,05,25,35,46,0

A217

AEC0144

GG2808

IPB1

ArborGen 2026 ASM

MARKET OPPORTUNITY
Build scale in Brazil, grow market share in US South

TOTAL MARKET

543M

178M

720M

119M

ADDRESSABLE

MARKET

ARBORGEN

CURRENT

VOLUME

667 MILLION

US SOUTH

(Loblolly Pine)

BRAZIL

Market size and Addressable Market

based on management estimates

and available market information

1.35 BILLION

1.2b Eucalyptus

150m Pine

Number of seedlings

ArborGen 2026 ASM

18

19
SHAREHOLDER DISCUSSION

ArborGen 2026 ASM

RESOLUTIONS
Resolution 1: That the Directors be authorised to fix the fees and

expenses of Grant Thornton as the Company’s auditor

Resolution 2: Re-election of Paul Smart as a Director of the Company

Resolution 3: Re-election of Thomas Avery as a Director of the Company

ArborGen 2026 ASM

20

21
OTHER BUSINESS

CLOSE OF THE MEETING

ArborGen 2026 ASM

22

ADJUSTED US GAAP RECONCILIATION
Fiscal year ending March US $mMar

2026

US GAAP

Revenue68.2

Gross margin (excluding DDA)22.4

LessSG&A (9.6)

LessR&D(2.5)

PlusOther income (expense)1.2

Adjusted US GAAP EBITDA

(3) (4)

11.5

Adjustments

Gain on sale of parcel of land0.2

Gain from ERC credits0.8


US GAAP EBITDA

(1) (2)

12.5

1.Under US GAAP, from a statutory reporting perspective, the classification of the

expense items, and other significant items in this table may differ from what is

presented in the financial statements.

2.US GAAP EBITDA excludes NZ public company costs.

3.Adjusted US GAAP EBITDA excludes one-off and unusual items which may include

restructure costs, impairments and write downs on assets, acquisition/sale

transaction costs and other one-off items. In FY26, one-off and unusual items were

$0.2m gain on sale of a parcel in Texas and an $800k gain for recognising an ERC tax

credit for which statute of limitations for potential audit has passed.

4.The Company uses Adjusted US GAAP EBITDA when discussing financial performance.

This is a non-GAAP financial measure and is not recognised within IFRS. Non-GAAP

financial measures should not be viewed in isolation nor considered as a substitute

for measures reported in accordance with GAAP. Management believes that

Adjusted US GAAP EBITDA provides useful information, as it is used internally to

evaluate performance, and it is also a measure that equity analysts focus on for

comparative company performance purposes, as themeasure removes distortions

caused by differences in asset age, depreciation policies and debt:equity structures.


ArborGen 2026 ASM

23

DISCLAIMER
This presentation has been prepared by ArborGen Holdings Limited (“ArborGen”), to provide an overview of the performance of ArborGen and its activities at the date of this presentation.

It is not prepared for any other purpose and must not be provided to any person other than the intended recipient. This presentation should be read in conjunction with ArborGen’s interim

and annual reports, market releases and other periodic and continuous disclosure announcements, which are available at www.nzx.com/companies/ARB and www.arborgenholdings.com.

The information in this presentation is of a general nature only. It is not a complete description of ArborGen.

This presentation is not a recommendation or offer of financial products for subscription, purchase or sale, or an invitation or solicitation for such offers.

This presentation is not intended as investment, financial or other advice and must not be relied on by any prospective investor. It does not take into account any particular prospective

investor’s objectives, financial situation, circumstances or needs, and does not purport to contain all the information that a prospective investor may require. Any person who is considering

an investment in ArborGen securities should obtain independent professional advice prior to making an investment decision, and should make any investment decision having regard to

that person’s own objectives, financial situation, circumstances and needs.

Past performance information contained in this presentation is not an indication of future performance and should not be relied upon as such. This presentation may also contain forward

looking statements with respect to the financial condition, results of operations and business, and business strategy of ArborGen. Information about the future, by its nature, involves

inherent risks and uncertainties. Accordingly, nothing in this presentation is a promise or representation as to the future or a promise or representation that a transaction or outcome

referred to in this presentation will proceed or occur on the basis described in this presentation. Statements or assumptions in this presentation as to future matters may prove to be

incorrect.

A number of financial measures are used in this presentation and should not be considered in isolation from, or as a substitute for, the information provided in ArborGen’s financial

statements available at www.arborgenholdings.com. This presentation may include non-GAAP financial measures. This information has been included on the basis that ArborGen

management and directors consider that this non-GAAP information assists readers to understand the key drivers of ArborGen’s performance which are not disclosed as GAAP measures in

ArborGen’s financial statements.

ArborGen and its related companies and their respective directors, employees and representatives make no representation or warranty of any nature (including as to accuracy or

completeness) in respect of this presentation and will have no liability (including for negligence) for any errors in or omissions from, or for any loss (whether foreseeable or not) arising in

connection with the use of or reliance on, information in this presentation.

All references to currencies in this document are in US dollars (US$) unless otherwise stated.

ArborGen 2026 ASM

24

Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.

Other issuers discussed similar conditions around this time

Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.

  • EBO — EBOS Group Limited: Annual Meeting Presentation
    2026-10-20

    “It also marked an important milestone. Over recent years, the Board has backed a significant program of investment to modernise our network and strengthen our portfolio. That facility investment cycle is now complete. As a result, EBOS goes into FY27 a stronger business. We ha…”

  • TWL — TradeWindow Holdings Limited: TWL Annual General Shareholders' Meeting - Presentation
    2026-09-29

    “V I R T U A L M E E T I N G How to participate –asking questions Shareholders and proxyholders can put questions to the board before and during the meeting. Written questions Questions may be submitted ahead of the meeting. During the meeting, select the Q&A tab on the right o…”

  • MCY — Mercury NZ Limited: Mercury 2026 Annual Shareholders' Meeting
    2026-09-18

    “2026 ASM – Chair and Chief Executive Addresses | 18 September 2026 | Page 5 of 5 As electricity demand grows, our focus is on bringing forward new renewable generation to support that growth, while continuing to maintain reliable electricity for homes, businesses, and communi…”